OPK

$1.19

Market ClosedAs of Mar 17, 8:00 PM UTC

OPKO Health, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.19
Potential Upside
5%
Whystock Fair Value$1.25
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$913.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-17.14%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.21

Recent News

Zacks
Feb 27, 2026

OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts

OPKO Health beats Q4 earnings and revenue estimates, but sales decline and gross margin narrows.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Moby
Feb 27, 2026

OPKO Health, Inc. Q4 2025 Earnings Call Summary

Moby summary of OPKO Health, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Feb 27, 2026

OPKO Health Q4 Earnings Call Highlights

OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 27, 2026

OPKO Health Inc (OPK) Q4 2025 Earnings Call Highlights: Strategic Divestitures and Promising ...

Despite a challenging quarter, OPKO Health Inc (OPK) focuses on core strengths and strategic partnerships to drive future profitability.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 27, 2026

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

Phillip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Elias Zerhouni, Vice Chairman and President, will then provide an overview of BioReference Health as well as OPKO Health, Inc.'s Therapeutics segment.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.